GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hemab Therapeutics Holdings, Inc. Common Stock COAG · USD

US listing · 🇺🇸 United States

Compare

42.81

-12.67%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hemab Therapeutics Holdings, Inc. Common Stock

Its shares trade under the ticker COAG. It has been listed since 1 May 2026.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
1 May 2026
Website
hemab.com ↗
Head office
101 MAIN STREET, CAMBRIDGE, MA, 02142
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Operates as a clinical-stage biotechnology company in the United States and Denmark.
  • Developing therapies for blood coagulation disorders with two clinical-stage assets.
  • Founded in 2020 with a focus on innovative treatments for rare blood disorders.

Weaknesses

  • Sector and industry are unknown, creating uncertainty for investors.
  • IPO scheduled for 2026-05-01, indicating limited current market presence.
  • No details provided on financial performance or revenue streams.

Opportunities

  • Potential to expand into new markets with clinical-stage assets in development.
  • Growing focus on rare blood disorder treatments could attract investment.
  • Collaboration opportunities with healthcare providers in the U.S. and Denmark.

Threats

  • Dependence on successful clinical trials for HMB-001 and HMB-002.
  • Uncertainty around sector and industry may deter potential investors.
  • IPO in 2026-05-01 leaves a long development timeline before market entry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.